RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Anixa Biosciences Stock

Anixa Biosciences EBIT 2024

Anixa Biosciences EBIT

-14.21 M USD

Ticker

ANIX

ISIN

US03528H1095

WKN

A2N6ZF

In 2024, Anixa Biosciences's EBIT was -14.21 M USD, a 30.93% increase from the -10.85 M USD EBIT recorded in the previous year.

The Anixa Biosciences EBIT history

YEAREBIT (undefined USD)
2028e-
2027e17.03
2026e-16.2
2025e-15.4
2024e-14.21
2023-10.85
2022-13.88
2021-12.75
2020-9.98
2019-11.3
2018-12.94
2017-6.06
2016-4.4
20152.56
2014-4.47
2013-7.81
2012-4.13
2011-5.02
2010-5.25
2009-7.32
2008-5.99
2007-5.49
2006-7.63
2005-4.47
2004-3.37

Anixa Biosciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Anixa Biosciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Anixa Biosciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Anixa Biosciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Anixa Biosciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Anixa Biosciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Anixa Biosciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Anixa Biosciences’s growth potential.

Anixa Biosciences Revenue, EBIT and net profit per share

DateAnixa Biosciences RevenueAnixa Biosciences EBITAnixa Biosciences Net Income
2028e36.31 M undefined0 undefined38.08 M undefined
2027e34.68 M undefined17.03 M undefined33.15 M undefined
2026e0 undefined-16.2 M undefined-7.88 M undefined
2025e0 undefined-15.4 M undefined-11.98 M undefined
2024e0 undefined-14.21 M undefined-12.97 M undefined
2023210,000 undefined-10.85 M undefined-9.81 M undefined
20220 undefined-13.88 M undefined-13.6 M undefined
2021510,000 undefined-12.75 M undefined-12.95 M undefined
20200 undefined-9.98 M undefined-10.02 M undefined
2019250,000 undefined-11.3 M undefined-11.65 M undefined
20181.11 M undefined-12.94 M undefined-14 M undefined
2017360,000 undefined-6.06 M undefined-7.02 M undefined
2016300,000 undefined-4.4 M undefined-5.02 M undefined
20159.26 M undefined2.56 M undefined-1.38 M undefined
20143.67 M undefined-4.47 M undefined-9.61 M undefined
2013390,000 undefined-7.81 M undefined-10.08 M undefined
2012940,000 undefined-4.13 M undefined-4.25 M undefined
20111 M undefined-5.02 M undefined-7.38 M undefined
2010730,000 undefined-5.25 M undefined-5.18 M undefined
20091.06 M undefined-7.32 M undefined-16.49 M undefined
20082.06 M undefined-5.99 M undefined-5.82 M undefined
2007490,000 undefined-5.49 M undefined-5.46 M undefined
2006510,000 undefined-7.63 M undefined-7.6 M undefined
2005440,000 undefined-4.47 M undefined-4.45 M undefined
2004490,000 undefined-3.37 M undefined-3.36 M undefined

Anixa Biosciences stock margins

The Anixa Biosciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Anixa Biosciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Anixa Biosciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Anixa Biosciences's sales revenue. A higher gross margin percentage indicates that the Anixa Biosciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Anixa Biosciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Anixa Biosciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Anixa Biosciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Anixa Biosciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Anixa Biosciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Anixa Biosciences Margin History

Anixa Biosciences Gross marginAnixa Biosciences Profit marginAnixa Biosciences EBIT marginAnixa Biosciences Profit margin
2028e97 %0 %104.86 %
2027e97 %49.12 %95.59 %
2026e97 %0 %0 %
2025e97 %0 %0 %
2024e97 %0 %0 %
202397 %-5,166.67 %-4,671.9 %
202297 %0 %0 %
202197 %-2,500 %-2,539.22 %
202097 %0 %0 %
201997 %-4,520 %-4,660 %
201897 %-1,165.77 %-1,261.26 %
201797 %-1,683.33 %-1,950 %
201697 %-1,466.67 %-1,673.33 %
201597 %27.65 %-14.9 %
201497 %-121.8 %-261.85 %
201397 %-2,002.56 %-2,584.62 %
201297 %-439.36 %-452.13 %
201197 %-502 %-738 %
201089.04 %-719.18 %-709.59 %
200993.4 %-690.57 %-1,555.66 %
200895.63 %-290.78 %-282.52 %
200767.35 %-1,120.41 %-1,114.29 %
200668.63 %-1,496.08 %-1,490.2 %
2005-63.64 %-1,015.91 %-1,011.36 %
200465.31 %-687.76 %-685.71 %

Anixa Biosciences Aktienanalyse

What does Anixa Biosciences do?

Anixa Biosciences Inc is a biotechnology company focused on the development and commercialization of cancer therapeutics. The company is headquartered in San Jose, California and was founded in 1982. The history of Anixa Biosciences Inc began as a subsidiary of VaxGen Inc, a now dissolved biotechnology company. Originally, Anixa focused on the development of vaccines for infectious diseases before shifting its focus to cancer therapeutics. Since 2016, Anixa Biosciences Inc has made rapid progress, particularly in the field of cancer immunotherapy. The company has formed several partnerships with other major pharmaceutical companies such as Cleveland Clinic and OntoChem to accelerate the development of treatments for various types of cancer. Anixa Biosciences Inc's business model is based on the development and commercialization of patented cancer therapeutics. Anixa has specialized in the development of immunotherapeutics based on its own proprietary technology platform. The company has specialized in three areas: cancer detection, immunotherapy, and antibody production. In cancer detection, the company is working on the development of diagnostic tools that enable doctors to detect and treat cancer at an early stage. In the field of immunotherapy, Anixa has developed various therapeutics that stimulate the body's immune system to attack and destroy cancer cells. The company has specifically developed immunotherapeutics that specialize in targeted attacks on cancer cells. In antibody production, Anixa focuses on the development of monoclonal antibodies that specifically target tumor cells. These antibodies can be used to identify and isolate cancer cells. Additionally, they can be used as carriers for drugs to provide targeted therapies against tumor cells. Another product of Anixa Biosciences Inc is the CchekTM blood test, which was developed for the detection of breast, ovarian, and prostate cancer. The blood test is based on the discovery of specific biomarkers that can indicate an increased presence of cancer cells in blood samples. In 2019, Anixa announced its entry into the rapidly growing market for in-vitro diagnostics. This market includes the development and commercialization of diagnostic tools used for disease identification and monitoring disease progression. Anixa plans to expand its expertise in cancer diagnostics to other disease areas such as cardiovascular diseases and neurological diseases. Overall, Anixa Biosciences Inc has a diverse portfolio of products specializing in the development of cancer therapeutics, diagnostic tools, and immune competence. The company works closely with established research and development companies to enhance its technologies and create new products. Anixa positions itself as an innovative and future-oriented company in the biotechnology industry. Anixa Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Anixa Biosciences's EBIT

Anixa Biosciences's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Anixa Biosciences's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Anixa Biosciences's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Anixa Biosciences’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Anixa Biosciences stock

How much did Anixa Biosciences achieve in EBIT for the current year?

In the current year, Anixa Biosciences has achieved an EBIT of -14.21 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Anixa Biosciences.

How has the EBIT of Anixa Biosciences developed in recent years?

The EBIT of Anixa Biosciences has increased by 30.931% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Anixa Biosciences?

The EBIT of Anixa Biosciences is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Anixa Biosciences pay?

Over the past 12 months, Anixa Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Anixa Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Anixa Biosciences?

The current dividend yield of Anixa Biosciences is .

When does Anixa Biosciences pay dividends?

Anixa Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Anixa Biosciences?

Anixa Biosciences paid dividends every year for the past 0 years.

What is the dividend of Anixa Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Anixa Biosciences located?

Anixa Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Anixa Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Anixa Biosciences from 11/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/17/2024.

When did Anixa Biosciences pay the last dividend?

The last dividend was paid out on 11/17/2024.

What was the dividend of Anixa Biosciences in the year 2023?

In the year 2023, Anixa Biosciences distributed 0 USD as dividends.

In which currency does Anixa Biosciences pay out the dividend?

The dividends of Anixa Biosciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Anixa Biosciences

Our stock analysis for Anixa Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Anixa Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.